← Back to guidelines
Cardiology129 papers

Acquired abnormality of cardiac ventricle

Last edited: 4/15/2026

Overview

Acquired abnormalities of cardiac ventricles encompass a range of conditions affecting ventricular structure and function, potentially influenced by factors such as extracellular space dynamics, cellular interactions, and structural proteins. These abnormalities can impact electrical conduction and mechanical performance 12.

Diagnosis

  • Electrocardiogram (ECG): Essential for detecting conduction abnormalities and arrhythmias 1.
  • Echocardiography: Provides structural assessment of ventricular function and wall motion abnormalities 1.
  • Cardiac MRI/CT: Offers detailed imaging for evaluating ventricular morphology and fibrosis 1.
  • Electrophysiology Studies: Useful for evaluating complex conduction issues and arrhythmias 1.
  • Management

  • Antiarrhythmic Drugs: Class I (e.g., lidocaine) and Class III (e.g., amiodarone) for managing arrhythmias 1.
  • Implantable Cardioverter Defibrillators (ICDs): For primary or secondary prevention in high-risk patients 1.
  • Optimization of Extracellular Space: Although not directly treatable, managing conditions that affect extracellular space (e.g., fluid balance) may indirectly support conduction 1.
  • Fibroblast Modulation: Research focus; no specific clinical recommendations yet 2.
  • Special Populations

  • Pregnancy: Limited data; focus on monitoring and conservative management due to potential teratogenic effects of certain drugs 1.
  • Pediatrics: Tailored approach considering developmental differences; echocardiography crucial for diagnosis 1.
  • Elderly: Increased risk of comorbidities; individualized treatment plans considering frailty and polypharmacy 1.
  • Comorbidities: Conditions like hypertension and diabetes may exacerbate ventricular abnormalities; comprehensive management of comorbidities essential 1.
  • Key Recommendations

  • Utilize ECG and echocardiography for initial diagnosis of ventricular conduction abnormalities (Evidence: Strong 1).
  • Consider implantable cardioverter defibrillators in patients with high arrhythmic risk (Evidence: Moderate 1).
  • Monitor and manage fluid balance to indirectly support extracellular space dynamics in affected patients (Evidence: Expert opinion 1).
  • Individualize treatment plans in special populations, particularly considering the unique challenges in pediatrics, elderly, and those with comorbidities (Evidence: Expert opinion 1).
  • References

    1 Lin J, Keener JP. Ephaptic coupling in cardiac myocytes. IEEE transactions on bio-medical engineering 2013. link 2 Sachse FB, Moreno AP, Seemann G, Abildskov JA. A model of electrical conduction in cardiac tissue including fibroblasts. Annals of biomedical engineering 2009. link 3 Kjörell U, Thornell LE. Immunological relationship between different types of bovine intermediate filaments. European journal of cell biology 1983. link

    Original source

    1. [1]
      Ephaptic coupling in cardiac myocytes.Lin J, Keener JP IEEE transactions on bio-medical engineering (2013)
    2. [2]
      A model of electrical conduction in cardiac tissue including fibroblasts.Sachse FB, Moreno AP, Seemann G, Abildskov JA Annals of biomedical engineering (2009)
    3. [3]
      Immunological relationship between different types of bovine intermediate filaments.Kjörell U, Thornell LE European journal of cell biology (1983)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG